REFERENCES
1. Memon D, Schoenfeld AJ, Ye D, et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024;42:209-224.e9.
2. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707-23.
3. Dong S, Li X, Huang Q, et al. Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs. Drug Resist Updat. 2025;81:101215.
4. Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118:9-16.
5. Le J, Sun Y, Deng G, Dian Y, Xie Y, Zeng F. Immune checkpoint inhibitors in cancer patients with autoimmune disease: safety and efficacy. Hum Vaccin Immunother. 2025;21:2458948.
6. Gettinger S, Choi J, Hastings K, et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017;7:1420-35.
7. Alsaafeen BH, Ali BR, Elkord E, et al. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol Cancer. 2025;24:20.
8. Sari G, Rock KL. Tumor immune evasion through loss of MHC class-I antigen presentation. Curr Opin Immunol. 2023;83:102329.
9. Martínez-Sabadell A, Arenas EJ, Arribas J. IFNγ signaling in natural and therapy-induced antitumor responses. Clin Cancer Res. 2022;28:1243-9.
10. He J, Xiong X, Yang H, et al. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Res. 2022;32:530-42.
11. Dulal D, Boring A, Terrero D, Johnson T, Tiwari AK, Raman D. Tackling of immunorefractory tumors by targeting alternative immune checkpoints. Cancers. 2023;15:2774.
